Research & Development

In collaboration with Jožef Stefan Institute, in particular with Mass Spectrometry Centre, we are developing an analytical method for trace analyses of specific cannabinoids.

National Institute of Biology, Ljubljana, the Department of Biopharmaceutics and Pharmacokinetics from Faculty of Pharmacy and School of Economics and Business, both from University of Ljubljana are project partners of the research project CANSAFE (see below), which is co-funded by Slovenian Research Agency. PharmaHemp is an industrial partner of this project.

We are also collaborating with the Department of Food Analysis and Nutrition, University of Chemistry and Technology, Prague on non-targeted analyses of unknown cannabinoids that occur in various types of purified and non-purified Cannabis extracts and finished products.

The most important current and past projects where PharmaHemp participated:

• Research project “Safety evaluation of cannabidiols and implications for public health and consumers behavior (CANSAFE) which is co-funded by the Slovenian Research Agency (2021-2023). Project partners are:
  • National Institute of Biology (NIB), Ljubljana;
  • Faculty of Pharmacy, University of Ljubljana
  • School of Economics and Business, University of Ljubljana
  • PharmaHemp (industrial partner)
• RRI project in collaboration with MycoMedica “First food supplement standardized to erinacine A” (2020-2022)
• RRI project “New generation of hemp extracts for natural cosmetics” (2018-2020)
• Project “Digital transformation of PharmaHemp d.o.o. (2021)
• Project “Upgrading e-commerce for expansion to foreign markets” (2019-2022)

We also collaborate with Paediatric Neurology Department at University Medical Centre Ljubljana, Slovenia. PharmaHemp is a sponsor of several clinical trials which involve treatment of children with specific conditions. The latest trial, “Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy (HemPhar)” is available here.